Novokuibyshevsk, Russian Federation

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

Phase Ia is divided into two phases of dose escalation and dose extension: This part includes dose escalation and dose extension of RP903 single agent to investigate the safety, tolerability, maximum tolerated dose and pharmacokinetic (PK) characteristics of RP903 single agent. Phase Ib is the clinical indication expansion phase, and the primary purpose of this phase is to evaluate the initial safety and anti-tumor efficacy in a selected indication target population. After determining RP903 monotherapy RP2D in Phase Ia, SMC will select four advanced malignant tumors with PIK3CA mutations (cervical cancer, endometrial cancer, breast cancer, and ovarian cancer) as indications for clinical expansion studies based on phase Ia efficacy, safety, and pharmacokinetic (PK) data. The dose was determined according to the results of the dose escalation phase and the dose extension phase.

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined with Durvalumab and Lenvatinib in Patients with Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

Adaptive Intervention Model for Hypertension Self-Management in Rural Areas: a Doctor-Patient Interaction Approach

Percutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale（PREDICT-PFO Trial）

The Application of Artificial Intelligence in Waist and Hand Joint Ultrasound

Research Background Musculoskeletal ultrasound, a rapidly evolving technique for ultrasound - based diagnosis and treatment of the musculoskeletal system, has seen expanding applications in visualizing peripheral nerves, muscles, tendons, joints, and skin thanks to improved ultrasound resolution. It offers advantages like convenience, cost - effectiveness, safety, real - time dynamics, continuous follow - up, and fast reporting. Given the high incidence and wide prevalence of rheumatic and immunological diseases, high - frequency ultrasound is gaining clinical attention. Consequently, learning and promoting musculoskeletal ultrasound is clinically valuable and necessary. However, this field faces challenges such as operator dependence, slow skill improvement and subjective differences in ultrasound diagnosis criteria and assessment methods for rheumatic diseases. The emergence of intelligent tools (AI) can address the urgent need for fast, accurate, and standardized ultrasound diagnosis. While AI has been used in multiple ultrasound sub - specialties, its application in musculoskeletal ultrasound is limited. This study aims to develop an AI - assisted musculoskeletal ultrasound examination system. It will help ultrasonographers by real - time segmenting structures like muscles, tendons, bone cortex, peripheral nerves, joint spaces, and blood vessels, extracting lesions (e.g., synovitis, tenosynovitis, bone erosion, cartilage destruction), and assessing lesion severity, thereby improving diagnostic accuracy and efficiency. Additionally, the system will shorten the learning cycle, enhance learning efficiency for musculoskeletal ultrasound, and accelerate its adoption in hospitals at all levels. Research Objectives Primary Objective: To develop a musculoskeletal ultrasound AI - assisted examination system. This system will identify standard examination sections and continuous dynamic images of wrist and hand joints, mark specific structures in real - time, extract lesions, and assess their severity, enhancing examination efficiency and accuracy. Secondary Objective: To help ultrasonographers shorten their learning period and master musculoskeletal ultrasound examination skills more quickly through the application of the AI - assisted system.

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving inhaled maintenance therapy and having had at least 2 moderate, or 1 severe, COPD exacerbations in the 12 months prior to Visit 1. Subjects will receive monthly subcutaneous injection of one of two different doses of tezepelumab, or placebo, with a maximum treatment duration of 76 weeks and a minimum of 52 weeks. The study also includes a off-treatment safety follow-up period of 12 weeks.

Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

Immune thrombocytopenia (ITP) Can be associated with various autoimmune diseases, including SLE, and SS. Patients with refractory thrombocytopenia often have long hospital stays, high medical costs, high demand for blood products, and are prone to complications of other systemic injuries. Such patients require active treatment to reduce the risk of life-threatening bleeding, delay the progression of the disease prognosis Glucocorticoids combined with immunosuppressive agents are still the main treatment strategies. Recently, biological agents targeting abnormal immune cells, such as rituximab and belimumab, which deplete B cells have also achieved some success in the treatment of ITP. However, these agents cannot permanently reverse the production of abnormal antibodies as they are unable to eliminate pathogenic long-lived plasma cells because these agents cannot penetrate lymph nodes and soft tissue. The BCMA-CD19 cCAR T-cells are designed to deplete antibody-producing 'root", B cells and plasma cells.

Nursing Interventions for Alzheimer's Patients During PET/CT Imaging

This study will analyze clinical data from 200 Alzheimer's disease (AD) patients who underwent PET imaging and were admitted to Sichuan Provincial People's Hospital over a period of six months. The control group will receive routine nursing intervention, while the observation group will receive a refined specialized nursing intervention. We will meticulously compare various performance aspects in both groups to assess the impact of refined specialized nursing intervention on patients' image quality and patient satisfaction.